title: How Failure Can Fuel Improvements in Early Drug Development for Inflammatory Bowel Diseases.
authors.affiliation: 1st Department of Internal Medicine and Institute of Clinical Molecular Biology, Christian-Albrechts-University Kiel, University Hospital Schleswig-Holstein, Kiel, Germany.
authors.forename: Stefan
authors.initials: S
authors.lastname: Schreiber
authors.affiliation: Department of Gastroenterology, University Hospitals Leuven Belgium.
authors.forename: Séverine
authors.initials: S
authors.lastname: Vermeire
mesh_terms: D000893:Anti-Inflammatory Agents / Q000009:adverse effects / Q000627:therapeutic use*; D015415:Biomarkers / Q000378:metabolism; D002986:Clinical Trials as Topic / Q000379:methods*; D003093:Colitis, Ulcerative / Q000175:diagnosis / Q000188:drug therapy* / Q000378:metabolism; D003424:Crohn Disease / Q000175:diagnosis / Q000188:drug therapy* / Q000378:metabolism; D055808:Drug Discovery / Q000379:methods*; D023381:Endpoint Determination; D005765:Gastrointestinal Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D018579:Patient Selection; D011237:Predictive Value of Tests; D012107:Research Design; D017211:Treatment Failure
chemical_list: D000893:Anti-Inflammatory Agents; D015415:Biomarkers; D005765:Gastrointestinal Agents